Drugs /

ny-eso-1/prame/mage-a3/wt-1 peptide vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A peptide-based cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. Upon administration, NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. The NY-ESO-1, PRAME, MAGE-A3 and WT-1 peptides, tumor-associated antigens (TAAs) overexpressed in a variety of cancer cell types, play a key role in tumor cell proliferation.

Clinical Trials

View Clinical Trials for ny-eso-1/prame/mage-a3/wt-1 peptide vaccine

Ny-eso-1/prame/mage-a3/wt-1 peptide vaccine has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating ny-eso-1/prame/mage-a3/wt-1 peptide vaccine, 1 is phase 1 (0 open).

BCR-ABL1 Fusion, Complex karyotype, and DEK-NUP214 Fusion are the most frequent biomarker inclusion criteria for ny-eso-1/prame/mage-a3/wt-1 peptide vaccine clinical trials.

Acute myeloid leukemia and myelodysplastic syndromes are the most common diseases being investigated in ny-eso-1/prame/mage-a3/wt-1 peptide vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ny-Eso-1/prame/mage-A3/wt-1 Peptide Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ny-eso-1/prame/mage-a3/wt-1 peptide vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
npmw peptide vaccine, ny-eso-1/prame/mage-a3/wt-1 peptide vaccine, npmw-peptide vaccine
NCIT ID [1]:
C127125

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.